DK1638589T3 - Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose - Google Patents

Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose

Info

Publication number: DK1638589T3
Authority: DK; Denmark
Prior art keywords: mitoxantrone; treatment; multiple sclerosis; combination therapy; glatiramer acetate
Prior art date: 2003-05-14

Application number

DK04752284.2T

Other languages

English (en)

Inventor

Timothy Vollmer

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-14

Filing date

2004-05-14

Publication date

2014-06-30

2004-05-14 Application filed by Teva Pharma filed Critical Teva Pharma

2014-06-30 Application granted granted Critical

2014-06-30 Publication of DK1638589T3 publication Critical patent/DK1638589T3/da

Links

108010072051 Glatiramer Acetate Proteins 0.000 title 1
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
229960003776 glatiramer acetate Drugs 0.000 title 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 title 1
229960001156 mitoxantrone Drugs 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK04752284.2T 2003-05-14 2004-05-14 Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose DK1638589T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47064003P	2003-05-14	2003-05-14
PCT/US2004/015225 WO2004103297A2 (en)	2003-05-14	2004-05-14	Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

Publications (1)

Publication Number	Publication Date
DK1638589T3 true DK1638589T3 (da)	2014-06-30

Family

ID=33476729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04752284.2T DK1638589T3 (da)	2003-05-14	2004-05-14	Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose

Country Status (11)

Country	Link
US (1)	US7968511B2 (da)
EP (1)	EP1638589B1 (da)
CA (1)	CA2525771A1 (da)
DK (1)	DK1638589T3 (da)
ES (1)	ES2466390T3 (da)
HR (1)	HRP20140524T1 (da)
IL (1)	IL171956A (da)
PL (1)	PL1638589T3 (da)
PT (1)	PT1638589E (da)
SI (1)	SI1638589T1 (da)
WO (1)	WO2004103297A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) *	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
SI1459065T1 (sl) *	2001-12-04	2010-11-30	Teva Pharma	Postopki za merjenje potentnosti glatiramer acetata
WO2005117902A1 (en) *	2004-05-28	2005-12-15	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
WO2006029411A2 (en) *	2004-09-09	2006-03-16	Yeda Research And Development Co. Ltd.	Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060172942A1 (en) *	2005-02-02	2006-08-03	Teva Pharmaceutical Industries, Ltd.	Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1957082B1 (en) *	2005-12-02	2012-04-11	The Johns Hopkins University	Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034071A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclophosphamide in combination with immune therapeutics
CN101883586A (zh) *	2007-10-01	2010-11-10	约翰斯霍普金斯大学	使用环磷酰胺治疗神经性自身免疫疾病
WO2009067699A2 (en) *	2007-11-21	2009-05-28	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) *	2007-11-21	2015-05-05	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
RU2390334C1 (ru) *	2008-12-17	2010-05-27	Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию"	Способ лечения рассеянного склероза
ES2424692T3 (es)	2009-08-20	2013-10-07	Yeda Research And Development Co., Ltd.	Terapia con acetato de glatirámero a baja frecuencia
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
WO2013009885A2 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation of copolymer diethylamide
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
WO2013055683A1 (en)	2011-10-10	2013-04-18	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
NZ630421A (en)	2012-10-10	2018-07-27	Teva Pharma	Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da)	2016-08-31	2023-07-31	Mapi Pharma Ltd	Depotsystemer, der omfatter glatirameracetat
JP7602322B2 (ja)	2017-03-26	2024-12-18	マピファーマリミテッド	進行型の多発性硬化症を治療するためのグラチラマーデポシステム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4617319A (en) *	1985-06-13	1986-10-14	American Cyanamid Company	Method of treating multiple sclerosis
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6531464B1 (en) *	1999-12-07	2003-03-11	Inotek Pharmaceutical Corporation	Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives

2004
- 2004-05-14 DK DK04752284.2T patent/DK1638589T3/da active
- 2004-05-14 PT PT47522842T patent/PT1638589E/pt unknown
- 2004-05-14 HR HRP20140524TT patent/HRP20140524T1/hr unknown
- 2004-05-14 PL PL04752284T patent/PL1638589T3/pl unknown
- 2004-05-14 SI SI200432163T patent/SI1638589T1/sl unknown
- 2004-05-14 EP EP04752284.2A patent/EP1638589B1/en not_active Expired - Lifetime
- 2004-05-14 ES ES04752284.2T patent/ES2466390T3/es not_active Expired - Lifetime
- 2004-05-14 US US10/556,454 patent/US7968511B2/en not_active Expired - Fee Related
- 2004-05-14 WO PCT/US2004/015225 patent/WO2004103297A2/en not_active Ceased
- 2004-05-14 CA CA002525771A patent/CA2525771A1/en not_active Abandoned
2005
- 2005-11-14 IL IL171956A patent/IL171956A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL171956A0 (en)	2006-04-10
EP1638589A4 (en)	2009-01-07
US7968511B2 (en)	2011-06-28
IL171956A (en)	2011-08-31
HRP20140524T1 (hr)	2014-12-19
EP1638589B1 (en)	2014-03-26
CA2525771A1 (en)	2004-12-02
SI1638589T1 (sl)	2014-07-31
WO2004103297A3 (en)	2005-03-17
PL1638589T3 (pl)	2014-10-31
EP1638589A2 (en)	2006-03-29
ES2466390T3 (es)	2014-06-10
US20070173442A1 (en)	2007-07-26
PT1638589E (pt)	2014-06-12
WO2004103297A2 (en)	2004-12-02

Publication	Publication Date	Title
DK1638589T3 (da)	2014-06-30	Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose
DK1487541T3 (da)	2009-01-19	Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
IL180992A0 (en)	2007-07-04	Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1663978T3 (da)	2008-04-07	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
PT1605956E (pt)	2016-03-09	Administração de capsaicinóides para o tratamento da osteoartrite
DK1663287T3 (da)	2009-11-09	Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1773361T4 (da)	2012-10-15	Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme
PL2878297T3 (pl)	2020-09-07	Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1773999T3 (da)	2010-01-18	Vaccine til forebyggelse og behandling af HIV-infektion
IL165860A0 (en)	2006-01-15	Administration of therapeutic viruses
IS7691A (is)	2005-02-09	Lyfjasamsetningar til að meðhöndla æxli
IL184037A0 (en)	2008-12-29	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
NO20050569D0 (no)	2005-02-02	Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
DK1487828T3 (da)	2009-02-02	Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20033123L (no)	2003-09-03	Terapeutisk hinne dannende sammensetning og behandlingsplan derav
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DK1670482T4 (da)	2022-08-22	Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DK1667693T3 (da)	2015-08-31	Præparater og fremgangsmåder til anvendelse af lamellare bodies til terapeutiske formål
DK1646378T3 (da)	2009-01-19	Farmaceutiske præparater omfattende ascorbinsyre til behandling af superinfektion med svamp og recidiv svamp
DK1553950T3 (da)	2007-10-15	Terapeutisk behandling
DK1687297T3 (da)	2014-09-22	Triazindimerer til behandling af autoimmunsygdomme